Brad Williams

George Goodman

- **Microbot Medical Inc. (MBOT)** will commercially debut its **LIBERTY® Endovascular Robotic System** at the Symposium on Clinical Interventional Oncology (CIO) annual meeting in Miami, FL, from **October 17-19, 2025**.  **[883975_0001493152-25-018260_ex99-1.htm:0]** **[883975_0001493152-25-018260_form8-k.htm:1]** 
- This event marks the **first U.S. commercial exhibition** of the LIBERTY® System following its **FDA 510(k) clearance in early September 2025**.  **[883975_0001493152-25-018260_ex99-1.htm:0]** **[883975_0001493152-25-018260_form8-k.htm:1]** 
- The company is on track to commence a **limited market release** of the LIBERTY® System in **Q4 2025**.  **[883975_0001493152-25-018260_ex99-1.htm:0]** **[883975_0001493152-25-018260_ex99-1.htm:1]** 
- To support commercialization, MBOT has completed the **hiring and on-boarding of its entire commercial leadership team**, including a Regional Sales Director, Sales Training Director, and Marketing Communications Manager.  **[883975_0001493152-25-018260_ex99-1.htm:0]** **[883975_0001493152-25-018260_form8-k.htm:1]** **[883975_0001493152-25-018260_ex99-1.htm:1]**

Microbot Medical to Commercially Debut LIBERTY System and Completes Commercial Team Hiring

- **Microbot Medical Inc. (MBOT) has partnered with a U.S. based third-party logistics (3PL) company** to support the commercialization of its **FDA-cleared LIBERTY® Endovascular Robotic System**.  **[883975_0001493152-25-017941_ex99-1.htm:0]** **[883975_0001493152-25-017941_form8-k.htm:1]** **[883975_0001493152-25-017941_form8-k.htm:2]** 
- The company expects to initiate the **limited market release of the LIBERTY® System during the fourth quarter of 2025**, with a **broader launch anticipated in April 2026**.  **[883975_0001493152-25-017941_ex99-1.htm:0]** **[883975_0001493152-25-017941_form8-k.htm:2]** 
- This partnership aims to ensure **effective and efficient inventory management and customer support** for the LIBERTY® System.  **[883975_0001493152-25-017941_ex99-1.htm:0]**

Microbot Medical Partners with Logistics Provider for LIBERTY System Commercialization

- **Microbot Medical Inc.** has partnered with a **U.S.-based third-party logistics (3PL) company** to support the commercialization of its **FDA-cleared LIBERTY® Endovascular Robotic System**.  **[883975_28f720427b194394a26306cf8310a574_0]** 
- The 3PL company specializes in the medical device industry, providing **effective and efficient order processing** and **inventory management** from a strategically located, climate-controlled warehouse.  **[883975_28f720427b194394a26306cf8310a574_0]** 
- The company is on track to initiate a **limited market release** of the LIBERTY® System during the **current fourth quarter of 2025**.  **[883975_28f720427b194394a26306cf8310a574_0]** 
- A **broader launch** of the LIBERTY® System is anticipated in **April 2026**.  **[883975_28f720427b194394a26306cf8310a574_0]**

Microbot Medical Secures U.S. Logistics Partner for LIBERTY® System Commercialization

- Microbot Medical Inc. announced the **third and final closing** of the exercise of outstanding preferred investment options on **October 7, 2025**.  **[883975_0001493152-25-017212_ex99-1.htm:0]** **[883975_0001493152-25-017212_form8-k.htm:3]** 
- The three closings generated approximately **$29.2 million** in gross proceeds  **[883975_0001493152-25-017212_ex99-1.htm:0]** **[883975_0001493152-25-017212_ex99-1.htm:1]**  and involved the purchase of an aggregate of **13,989,115 shares of common stock**.  **[883975_0001493152-25-017212_ex99-1.htm:0]** 
- The company also issued new unregistered short-term series J preferred investment options, which could generate up to an additional approximately **$63 million** in gross proceeds if fully exercised.  **[883975_0001493152-25-017212_ex99-1.htm:0]** **[883975_0001493152-25-017212_ex99-1.htm:1]**  These new options have an exercise price of **$4.50 per share**, are exercisable beginning six months after issuance, and have a two-year term.  **[883975_0001493152-25-017212_ex99-1.htm:0]** 
- The net proceeds from the offering are intended for the continued development, commercialization, and regulatory activities for the LIBERTY® Robotic System, potential acquisitions, expansion of existing IP portfolio applications, working capital, and other general corporate purposes.  **[883975_0001493152-25-017212_ex99-1.htm:1]**

Microbot Medical Announces Final Closing of Preferred Investment Options Exercise

- Microbot Medical Inc. announced the **third and final closing** of the exercise of certain outstanding preferred investment options on **October 7, 2025**.  **[883975_65720684cda54e379cc167bab51187b5_0]** 
- This exercise involved the purchase of an aggregate of **13,989,115 shares** of common stock across three tranches.  **[883975_65720684cda54e379cc167bab51187b5_0]** 
- The company received approximately **$29.2 million** in gross proceeds from these closings.  **[883975_65720684cda54e379cc167bab51187b5_1]** 
- In consideration for the exercise, Microbot issued new unregistered short-term series J preferred investment options, which, if fully exercised, could generate approximately **$63 million** in additional gross proceeds.  **[883975_65720684cda54e379cc167bab51187b5_0]** **[883975_65720684cda54e379cc167bab51187b5_1]** 
- The net proceeds from the offering are intended for the continued development, commercialization, and regulatory activities for the **LIBERTY® Robotic System**, potential acquisitions, and general corporate purposes.  **[883975_65720684cda54e379cc167bab51187b5_1]**

Microbot Medical Completes Exercise of Preferred Investment Options, Securing $29.2 Million in Gross Proceeds

- On **October 1, 2025**, Microbot Medical Inc. announced the **Japanese Patent Office granted its first patent in Japan** for the core LIBERTY® System technology, covering a compact robotic device for surgical tools.  **[883975_0001493152-25-016484_ex99-1.htm:0]** **[883975_0001493152-25-016484_form8-k.htm:1]** **[883975_0001493152-25-016484_form8-k.htm:2]** 
- This patent adds to recent intellectual property gains, including patents in the **U.S., China, and Israel** within the last 90 days.  **[883975_0001493152-25-016484_ex99-1.htm:0]** 
- The company received **FDA marketing clearance for the LIBERTY® System on September 8, 2025**, and is accelerating its commercial launch, with an initial focus on the U.S. market.  **[883975_0001493152-25-016484_ex99-1.htm:0]**

Microbot Medical Inc. Secures First Japanese Patent and Advances LIBERTY® System Commercialization

- Microbot Medical Inc. announced that its CEO, Harel Gadot, will discuss the recent **FDA clearance** of the **LIBERTY® Endovascular Robotic System**.  **[883975_0001493152-25-014557_ex99-1.htm:0]** 
- The company received **FDA 510(k) clearance** for commercialization of the LIBERTY® Endovascular Robotic System on **September 8, 2025**.  **[883975_0001493152-25-014557_ex99-1.htm:0]** 
- The CEO will detail plans for the system's **commercialization in the U.S.**.  **[883975_0001493152-25-014557_ex99-1.htm:0]** 
- This discussion will take place during a live interview on **Benzinga All Access Live** on **September 24, 2025, at 10:45am ET**.  **[883975_0001493152-25-014557_ex99-1.htm:0]**

Microbot Medical CEO to Discuss FDA Clearance and Commercialization of LIBERTY® System

- Microbot Medical Inc. has entered into definitive agreements for the exercise of certain outstanding preferred investment options to purchase up to an aggregate of **13,989,115 shares** of common stock.  **[883975_d94e2407768f4ae58794f415aed30dfe_0]** 
- The offering is expected to close in **two tranches**, with the first closing anticipated on or about **September 16, 2025**, and the second by no later than **October 15, 2025**.  **[883975_d94e2407768f4ae58794f415aed30dfe_0]** 
- The company expects to receive approximately **$25.2 million** in gross proceeds from the first closing and approximately **$4 million** from the second closing.  **[883975_d94e2407768f4ae58794f415aed30dfe_1]** 
- Additionally, the potential gross proceeds from the new short-term series J preferred investment options, if fully exercised, could be approximately **$63 million**, bringing the total potential gross proceeds to approximately **$92.2 million**.  **[883975_d94e2407768f4ae58794f415aed30dfe_1]** 
- The net proceeds are intended for the continued development, commercialization, and regulatory activities for the **LIBERTY® Robotic System**, potential acquisitions, expansion of IP portfolio applications, and for working capital and other general corporate purposes.  **[883975_d94e2407768f4ae58794f415aed30dfe_1]**

Microbot Medical Announces Exercise of Preferred Investment Options for Up to $92.2 Million in Gross Proceeds

- Microbot Medical Inc. issued an aggregate of **4,055,870 shares** of its common stock between **August 26, 2025, and August 27, 2025**.  **[883975_0001641172-25-025709_form8-k.htm:1]** 
- These shares were issued upon the exercise of **300,000 Series H preferred investment options** and **3,755,870 Series I preferred investment options**.  **[883975_0001641172-25-025709_form8-k.htm:1]** 
- The exercise of these options generated approximately **$8.6 million** in aggregate gross proceeds for the company.  **[883975_0001641172-25-025709_form8-k.htm:1]**  As of **August 27, 2025**, the company had approximately **52,569,762 shares** of common stock issued and outstanding.  **[883975_0001641172-25-025709_form8-k.htm:1]**

Microbot Medical (MBOT)